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Aims: The current pandemic coronavirus SARS-CoV-2 infects a wide age-group but 2 
predominantly elderly individuals, especially men and those with cardiovascular disease. 3 
Recent reports suggest an association with use of renin-angiotensin-aldosterone system 4 
(RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for 5 
coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-6 
CoV-2 in patients on RAAS-inhibitors.  7 
Methods: We measured ACE2 concentrations in 1485 men and 537 women with heart failure 8 
(Index cohort). Results were validated in 1123 men and 575 women (Validation cohort). 9 
Results: The median age was 69 years for men, and 75 years for women. The strongest 10 
predictor of elevated concentrations of ACE2 in both cohorts was male sex (estimate=0.26, 11 
p<0.001 and 0.19; p<0.001 respectively). In the index cohort, use of ACE-inhibitors, 12 
angiotensin receptor blockers (ARBs) or mineralocorticoid receptor antagonists (MRAs) were 13 
not independent predictors of plasma ACE2. In the validation cohort, ACE-inhibitor 14 
(estimate=-0.17; p=0.002) and ARB use (estimate=-0.15; p=0.03) were independent 15 
predictors of lower plasma ACE2, while use of a MRA (estimate=0.11; p=0.04) was an 16 
independent predictor of higher plasma ACE2 concentrations.  17 
Conclusion: In two independent cohorts of patients with heart failure, plasma concentrations 18 
of ACE2 were higher in men than women, but neither use of an ACE-inhibitor nor an ARB 19 
was associated with higher plasma ACE2 concentrations. These data might explain the higher 20 
incidence and fatality rate of COVID-19 in men, but do not support previous reports 21 
suggesting that ACE-inhibitors or ARBs increase the vulnerability for COVID-19 through 22 
increased plasma ACE2 concentrations.  23 
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Introduction  1 
The world is currently faced with the outbreak of a new Severe Acute Respiratory Syndrome 2 
coronavirus (SARS-CoV). The new virus, SARS-CoV-2 emerged in December 2019 in the 3 
city of Wuhan China, and is the causative agent of a respiratory syndrome now known as 4 
coronavirus disease 2019 (COVID-19)1, 2. Efforts aimed at curbing the spread of SARS-CoV-5 
2 and finding effective treatments are ongoing. 6 
Early epidemiological observations indicate that SARS-CoV-2 infects all age-groups, but 7 
older men with chronic illnesses may be more severely affected. There is a preponderance of 8 
men (58.1%) compared to women (41.9%) testing positive for COVID-192 and in the 9 
previous SARS-CoV epidemic in 2003, men had a higher mortality than women (21.9% 10 
versus 13.2%; p<0.0001)3. Whether men with the current SARS-CoV-2 virus also have a 11 
worse mortality outcome is becoming apparent as recent report indicate that 70% of patients 12 
that died of COVID-19 in Italy were men4; and mainly elderly. 13 
The increased vulnerability of older people with cardiovascular disease and comorbid 14 
conditions could be related to increased concentrations of angiotensin-converting enzyme 2 15 
(ACE2)5, 6, and ACE2 is known to be increased in heart failure7. ACE2 is not only an enzyme 16 
but also a functional receptor on cell-surfaces for both SARS-CoV and SARS-CoV-2 and is 17 
highly expressed in the heart, testis, kidneys and lungs8-12 and shed into the plasma. Some 18 
reports have suggested that inhibitors of the renin-angiotensin-aldosterone system (RAAS) 19 
increase plasma ACE2 concentrations5, 13, although these speculations are not supported by a 20 
substantial body of research.  21 
We therefore investigated plasma concentrations of ACE2 in two large and independent 22 





Study participants  2 
From the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) 3 
14, we measured ACE2 concentrations in 1485 men and 537 women with heart failure in 11 4 
European countries. Results were validated in another, independent BIOSTAT-CHF cohort 5 
consisting of 1123 men and 575 women with heart failure enrolled in Scotland. Only 6 
participants with sufficient plasma samples were used for this research. The design and 7 
baseline characteristics of both cohorts of BIOSTAT-CHF have been published elsewhere14. 8 
Inclusion criteria were the same in the index and validation cohorts; the only exception was 9 
that when the left ventricular ejection fraction (LVEF) was > 40%, patients had to have a 10 
BNP >400ng/L or NT-proBNP >2,000ng/L in the index cohort, but not in the validation 11 
cohort. The study complied with the Declaration of Helsinki and was approved by the medical 12 
ethics committees of participating centers14. 13 
ACE2 was measured using the Olink Proseek analysis service (Olink Proteomics, Uppsala, 14 
Sweden). The Olink platform15 utilizes a high-throughput multiplex immunoassay based on a 15 
proprietary Proximity Extension Assay (PEA) technology, where each biomarker is addressed 16 
by a matched pair of antibodies, coupled to unique, partially complementary oligonucleotides, 17 
and measured by quantitative real-time polymerase chain reaction (PCR). Results are 18 
expressed in the form of relative quantification (Normalized Protein eXpression or NPX) 19 
which are logarithmically related to protein concentration but cannot be converted to absolute 20 
protein concentrations. Interpretations are therefore relative and not absolute. Analytical 21 
validation of the sensitivity and specificity of the Olink assay for this study was achieved by 22 
comparing available routine laboratory measurements of two protein biomarkers, GDF15 23 
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(pg/mL) and NT-proBNP (pg/mL) with those measured using Olink (NPX). NT-proBNP is a 1 
canonical biomarker in cardiovascular disease biology16. 2 
Statistical Analyses 3 
All statistical analyses were performed using R17 version 3.6.2. In group comparisons, 4 
categorical variables were depicted as numbers with percentages. Normally distributed 5 
variables were depicted as means ± standard deviation, non-normally distributed variables as 6 
median and interquartile range (IQR) defined as the first and third quartile (Q1–Q3). The 7 
means for continuous variables were compared by one-way analysis of variance (ANOVA) or 8 
the Kruskal–Wallis test, while categorical variables were compared by the Chi-squared test. 9 
Multivariate models were based on backward stepwise regression. Baseline tables were made 10 
using the R-based CompareGroups18 package. In general, a two-tailed p-value of <0.05 was 11 
considered statistically significant. 12 
 13 
Results  14 
Clinical characteristics  15 
Baseline characteristics of the index and validation cohort are presented in table 1 and 16 
supplemental table 1 respectively. In the index cohort (n=2022), the median age was 69 years 17 
in men (interquartile range, IQR, 60-76), and for women 75 years (IQR 64-81; p<0001 18 
between men and women). In the validation cohort (n=1698), the median age for men was 74 19 
years (IQR 66-81) and for women 76 years (IQR 69-82; p< 0.001 between men and women). 20 
In the index cohort, patients with higher concentrations of ACE2 were more often men, were 21 
more likely to have atrial fibrillation and a higher heart rate and lower systolic blood pressure 22 
(table 1). In the validation cohort, patients with higher concentrations of ACE2 were more 23 
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often men, were more likely to have atrial fibrillation and diabetes and a higher heart rate and 1 
lower systolic blood pressure (supplemental table 1). In the index cohort, only 0.3% (6/2022) 2 
patients received both ACEi and ARB. In the validation cohort only 0.4% (7/1691) received 3 
both ACEi and ARB.  4 
Among patients that were not treated with RAAS-inhibitors, men were predominant in the 5 
uppermost quartile of ACE2 (supplemental table 2 and 3). ACE2 concentrations were higher 6 
in men than women in 9/11 countries but were similar by ACEi/ARB use (Supplemental 7 
Figure 1 and 2). 8 
Analytical validation of the Olink assay 9 
In both study cohorts, routine lab concentrations of two golden standard biomarkers (GDF-15 10 
and NT-proBNP) showed a strong correlation with those measured using Olink (Spearman’s 11 
rho 0.77-0.92, p<0.001; Supplemental Figure 3).  12 
ACE2 concentrations in men and women according to the use of RAAS-inhibitors 13 
The ACE2-RAAS-COVID-19 axis is summarized in Figure 1. In both cohorts, plasma ACE2 14 
concentrations (in NPX units) were higher in men than in women. In the index cohort, mean 15 
plasma concentration was 5.38 in men compared with 5.09 in women (p<0.001). In the 16 
validation cohort, mean plasma concentration was 5.46 in men compared with 5.16 in women 17 
(p<0.001). 18 
Figure 2 shows plasma ACE2 concentrations in those treated with or without blockers of the 19 
renin-angiotensin-aldosterone system. In the index cohort, mean plasma concentration was 20 
5.32 in patients who used an ACE-inhibitor compared with 5.29 in those who did not (p = 21 
0.59. In the validation cohort, mean plasma concentration was 5.32 in those who used an 22 
ACE-inhibitor versus 5.4 in those who did not (p = 0.0033). In the index cohort, mean plasma 23 
9 
 
concentration was 5.23 in patients who used an ARB compared with 5.31 in those who did 1 
not (p = 0.16). In the validation cohort, mean plasma concentration was 5.3 in those who used 2 
an ARB versus 5.37 in those who did not (p = 0.38). In the index cohort, mean plasma 3 
concentration was 5.35 in patients who used an MRA compared with 5.25 in those who did 4 
not (p = 0.003). In the validation cohort, mean plasma concentration was 5.4 in those who 5 
used an MRA versus 5.34 in those who did not (p = 0.036).  6 
Age and sex interaction analyses indicated that men who used MRA have an increased ACE2 7 
concentration (p  0.01, for models unadjusted, and those adjusted for ACEi use, ARB use, 8 
age, diabetes and atrial fibrillation). This was statistically significant only in the index cohort. 9 
In the validation cohort, men who used ACEi had lower ACE2 concentrations (p<0.05; for 10 
models unadjusted, and those adjusted for ACEi use, ARB use, age, diabetes and atrial 11 
fibrillation). All similar interaction tests were not statistically significant. 12 
Variables associated with plasma ACE2 concentrations 13 
The strongest predictor of elevated plasma concentrations of ACE2 in the index and 14 
validation cohort was male sex (estimate=0.26, p<0.001 and 0.19; p<0.001 respectively). In 15 
the index cohort, neither ACE-inhibitors, ARBs nor MRAs were associated with plasma 16 
ACE2 concentrations (table 2). In the validation cohort, ACE-inhibitors (estimate=-0.17; 17 
p=0.002) and ARBs (estimate=-0.15;p=0.03) were associated with lower plasma ACE2 18 
concentrations, but MRAs (estimate=0.11;p=0.04) were associated with higher concentrations 19 





In two large independent cohorts of patients with heart failure, we found that plasma ACE2 1 
concentrations were higher in men than in women. In addition, those receiving ACE-2 
inhibitors or ARBs did not have higher concentrations of ACE2 and an increase in those 3 
taking MRA in the validation cohort was not confirmed in the index cohort. 4 
There is an increased susceptibility of elderly people with chronic comorbidities to SARS 5 
coronaviruses and men appear to be especially vulnerable to SARS-CoV-21, 2, 19. Given that a 6 
typical heart failure patient belongs to this high-risk group, we sought to uncover factors that 7 
could explain the sex-based susceptibility to SARS-CoV-2 in this vulnerable population. 8 
Baseline characteristics of the two cohorts presented are typical for patients with heart failure 9 
and confirm that these are elderly patients that often have comorbidities, including diabetes, 10 
hypertension, renal disease and COPD. The spectrum of comorbidities involves most of the 11 
organs affected in COVID-19, including the heart, lungs, kidneys and liver1.  12 
COVID-19 patients and other patients with such underlying diseases are in a hyper-13 
inflammatory state. As such it might well be that patients with various kidney diseases have 14 
high endothelial ACE220; making ACE2 a damage marker. Furthermore, plasma ACE2 15 
activity is increased in patients with heart failure21.  16 
Post-transcriptional events of ACE2 in the testis 17 
ACE2 is widely distributed in tissues including lung alveolar epithelial cells, vascular 18 
endothelium, heart, kidney and testis8, 11, 20, 22. For the readers’ convenience, we provide 19 
Supplemental Figures 4 and 5 showing the gene structure of ACE2, and its isoforms and 20 
tissue distribution). ACE2 protein and interestingly also the non-coding isoforms are highly 21 
expressed in the testis22 (Supplemental Figure 6). Isoform transcription could possibly affect 22 
protein translation in this male-specific tissue; for example via MicroRNA (miRNA) 23 
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competition. Previous studies indicate that ACE2 may be subject to post-transcriptional 1 
regulation via miR-42123 which could be exploited as a novel potential therapeutic target to 2 
modulate ACE2 expression in disease. How the testis-expressed ACE2 protein, or those 3 
expressed at other organs, enters circulation is largely unknown. The tissue-specific 4 
transcriptional regulation of ACE2 could partially explain higher ACE2 protein 5 
concentrations and why a coronavirus would flourish in men. 6 
ACE2 plasma concentrations and use of RAAS-inhibitors 7 
Recently, it was suggested that the higher prevalence and fatality rate in patients with cardiac 8 
diseases, such as hypertension or diabetes, was related to the concomitant use of ACE-9 
inhibitors and ARBs that were suggested to increase ACE2 concentrations. The authors 10 
speculated that this might be due to increased expression of ACE2 but offered no evidence for 11 
this5, 6, 24, 25. In animal models, selective blockade of either Angiotensin II synthesis or activity 12 
induced increases in cardiac ACE2 gene expression and cardiac ACE2 activity13, whether this 13 
translates to humans needs to be validated.  14 
To the best of our knowledge, this is the first substantial study to examine the association 15 
between plasma ACE2 concentrations and the use of RAAS-blockers in patients with 16 
cardiovascular disease. In contrast to previous reports5, 6, 24, 25, ACE-inhibitors and ARBs were 17 
not associated with increased plasma concentrations of ACE2 in the present study. Indeed, if 18 
anything, the use of ACE-inhibitors and ARB predicted lower concentrations of ACE2 in the 19 
validation cohort, although these findings were not replicated in the index cohort. Taken 20 
together, these data do not support withholding ACE-inhibitors or ARBs in patients at risk for 21 
SARS-CoV-2 infection. 22 
12 
 
In the validation cohort, MRA use was associated with a weak but statistically significant 1 
increase in plasma ACE2 concentrations. Univariate and multivariate-adjusted analyses 2 
indicated a significant sex-based interaction; with men on MRA having higher ACE2 3 
concentrations. A similar association was, not found in the index cohort. The effect of MRA 4 
on plasma ACE2 is therefore not clear. One study found a trend (p=0.07) towards increased 5 
plasma ACE2 activity in patients treated with an MRA21. In addition, one mechanistic study 6 
using macrophages reported an increase of ACE2 activity after MRA26 but further data are not 7 
available. Clearly, our findings do not suggest that MRAs should be discontinued in patients 8 
with heart failure, in whom coronavirus SARS-CoV-2 infection is found. Moreover, even if 9 
MRAs are consistently found to increase plasma ACE2 concentrations, it still needs to be 10 
established whether their use is associated with higher vulnerability to or more severe 11 
consequences of SARS-CoV-2 infection. MRAs are a very effective treatment for heart 12 
failure and these hypothetical effects on viral infection should be weighed carefully against 13 
their proven benefits. 14 
The equilibrium between soluble and membrane-bound ACE2 might influence COVID-19 15 
pathogenesis and treatment options. Previous studies indicate ADAM17 16 
mediated ACE2 shedding27, 28 , but how this would affect coronavirus infectivity during 17 
concomitant use of RAAS inhibitors warrants a separate research. A study on dogs with heart 18 
disease indicated that ACE2 shedding is not an important factor in the total extent of 19 
tissue‐bound ACE2 activity, but rather a loss of tissue ACE2 into the circulation would tend 20 
to decrease the overall compensatory potential of ACE229. Further work is required to show 21 
whether this translates to humans. 22 
 23 
Conclusion:  24 
13 
 
In two large cohorts of patients with heart failure, plasma ACE2 concentrations were higher in 1 
men than in women, possibly reflecting higher tissue expression of this receptor for SARS 2 
coronavirus infections. This could explain why men might be more susceptible to infection 3 
with, or the consequences of, SARS-CoV-2. Patients receiving ACE-inhibitors or ARBs did 4 
not have higher plasma concentrations of ACE2 and any effect of MRA was small and 5 
inconsistent, supporting the continued use of these agents in patients with heart failure during 6 
the current SARS-CoV-2 pandemic. 7 
 8 
Limitations 9 
The conclusions drawn in this analysis are mainly restricted to heart failure, albeit a group of 10 
patients at high risk for COVID-19. Secondly, since our patients are not coronavirus-infected, 11 
we cannot provide a direct link between the course of COVID-19 disease in patients with low 12 
versus high plasma ACE2 concentrations, and the influence of age and RAAS-blockers on the 13 
course of the disease. Thirdly, we measured plasma ACE2 concentrations and not membrane-14 
bound ACE2. We can only speculate that circulating concentrations are associated with tissue 15 
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